Remote multimodal monitoring of motor neuron disease progression using wearable sensors and digital assessments (S14.010)

Abstract

<h3>Objective:</h3> To develop and assess the feasibility of a robust multi-modal platform to remotely monitor motor neuron disease (MND) symptoms and disease progression using wearable sensors and digital assessments of speech, handwriting, and pattern-tracing skills. <h3>Background:</h3> Frequent remote assessments of different disease symptoms and progression are critical in improving care for patients with neurological disorders and clinical trial readiness. There is a need for a multi-modal technological solution to objectively measure and monitor disease progression in MND. <h3>Design/Methods:</h3> Participants with MND were enrolled for up to 12 months of remote monitoring. They wore PAMSys™ pendant sensors for the duration of study to measure physical activity, walking parameters, postural transition, and falls during activities of daily living. Digital speech and handwriting and pattern tracing skill assessments were performed using the BioDigit Home™ (BioSensics LLC) tablet on biweekly basis. <h3>Results:</h3> To date, nine participants have been enrolled (4 female), with a median age of 69 years (range 44–2 years). High compliance for the pendant-sensor-based physical activity monitoring was observed and provided a reliable tool to assess fall risk in patients with MND (with some subjects having up to 1.5 confirmed falls per week and one reported near fall per week). Furthermore, on average, subjects completed 91.9% (range 53.8%–100%) of assigned speech task. 88% of the participants were able to perform handwriting and pattern-tracing tasks. <h3>Conclusions:</h3> Our preliminary results demonstrate the feasibility of the multi-modal telemonitoring solution to remotely monitor mobility and disease symptoms in MND. The longitudinal monitoring may address the problem of subjective biases, measure functional changes over time, and compensate for the impact of biological variability in intermittent single visits. Patient recruitment and data collection is ongoing, and the most updated results will be presented during the meeting. <b>Disclosure:</b> The institution of Andrew Geronimo has received research support from BioSensics, LLC. Mr. Casado has received personal compensation for serving as an employee of BioSensics LLC. Dr. Mishra has received personal compensation for serving as an employee of Biosensics. Mr. Lim has nothing to disclose. Dr. Vaziri has received personal compensation for serving as an employee of Biosensics. Dr. Simmons has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cytokinetics. The institution of Dr. Simmons has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amylyx. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector. Dr. Simmons has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Corcept. The institution of Dr. Simmons has received personal compensation in the range of $100,000-$499,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. The institution of Dr. Simmons has received research support from MGH. The institution of Dr. Simmons has received research support from MT Pharma. The institution of Dr. Simmons has received research support from University of Kansas. The institution of Dr. Simmons has received research support from ALS Association.